Valuation: Sunflower Pharmaceutical Group Co., Ltd.

Market Cap 6.57B 984M 875M 811M 735M 1.38B 93.18B 1.4B 9.74B 3.82B 48.76B 3.69B 3.61B 156B P/E 2024
24.4x
P/E 2025 -33.6x
Enterprise Value 4.08B 610M 543M 504M 456M 858M 57.83B 872M 6.04B 2.37B 30.26B 2.29B 2.24B 96.55B EV / Sales 2024
2.87x
EV / Sales 2025 2.65x
Free-Float
42.02%
Yield 2024
2.44%
Yield 2025 1.35%
10-14 Sunflower Pharmaceutical Gets Board Nod to Cancel Wholly-Owned Subsidiary MT
10-12 Harbin Hongye Pharmaceutical Co., Ltd. announced that it has received CNY 4 million in funding from Sunflower Pharmaceutical Group Co., Ltd. CI
10-12 Heilongjiang Dongxu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 5 million in funding from Sunflower Pharmaceutical Group Co., Ltd. CI
09-22 Sunflower Pharmaceutical Group Co., Ltd. agreed to acquire Heilongjiang Dongxu Pharmaceutical Co., Ltd. from Yang Dongxu and Yang Huaizhou for CNY 0.78 million. CI
08-28 Sunflower Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
07-28 Sunflower Pharmaceutical Withdraws Investment in Fund MT
07-28 Sunflower Pharmaceutical Commits 10 Million Yuan to Set Up Subsidiary in Sichuan, China MT
07-28 Sunflower Pharmaceutical Offloads Beijing Pharmastar Stake for 34 Million Yuan MT
07-26 Guangzhou Baiyunshan Hejigong Pharmaceutical Co., Ltd. agreed to acquire 10.39% stake in Beijing Pharmstar Pharmaceutical Technology from Sunflower Pharmaceutical Group Co., Ltd. for CNY 34.3 million. CI
05-25 Sunflower Pharmaceutical Group Co.,Ltd Approves Cash Dividend for 2025 CI
05-06 Sunflower Pharmaceutical Products Selected for Bulk Chinese Medicine Procurement MT
04-29 Sunflower Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-26 Sunflower Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on July 17, 2026 CI
1 day-0.53%
1 week-0.71%
Current month-1.32%
3 months-17.64%
6 months-8.61%
Current year-23.83%
1 week 11.1
Extreme 11.1
11.43
1 month 11.1
Extreme 11.1
11.62
Current year 11.04
Extreme 11.04
15.19
1 year 11.04
Extreme 11.04
15.66
3 years 11.04
Extreme 11.04
30.79
5 years 11.04
Extreme 11.04
31.48
10 years 11.04
Extreme 11.04
31.48
Manager TitleAgeSince
Chief Executive Officer 58 2026-02-08
Director of Finance/CFO 49 2021-12-05
Corporate Officer/Principal 56 2025-03-19
Director TitleAgeSince
Director/Board Member 66 2014-03-25
Director/Board Member 64 2017-09-25
Director/Board Member 44 2017-09-25
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/24 Buy 500 0.0001%
1/22/20 Sell

Director

246,300 0.0462%
1/1/20 Sell 21,300 0.0040%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-0.71%-26.52%-51.98% 988M
+3.49%+10.04%+58.68%+119.56% 1,106B
+2.19%+4.32%+33.88%+69.52% 612B
+2.26%+5.37%+24.57%+97.69% 500B
+2.58%+8.37%+38.71%+63.14% 367B
+3.25%+4.45%+71.80%+44.44% 354B
+1.85%+6.04%+21.47%+49.17% 286B
+1.76%+6.07%+0.43%+20.98% 256B
+3.29%+6.32%+44.71%+57.43% 230B
+2.25%+5.81%+27.13%+101.17% 190B
Average +1.79%+3.64%+29.49%+57.11% 390.11B
Weighted average by Cap. +1.43%+4.67%+40.80%+80.55%

Financials

2024 2025
Net sales 3.38B 506M 450M 417M 378M 710M 47.89B 722M 5B 1.97B 25.06B 1.9B 1.86B 79.96B 2.32B 347M 309M 286M 259M 488M 32.87B 496M 3.43B 1.35B 17.2B 1.3B 1.27B 54.88B
Net income 492M 73.66M 65.57M 60.77M 55.06M 103M 6.98B 105M 729M 286M 3.65B 276M 271M 11.65B -258M -38.6M -34.36M -31.84M -28.85M -54.23M -3.66B -55.13M -382M -150M -1.91B -145M -142M -6.1B
Net Debt -2.29B -343M -305M -283M -256M -482M -32.47B -490M -3.39B -1.33B -16.99B -1.29B -1.26B -54.21B -2.49B -373M -332M -308M -279M -524M -35.34B -533M -3.69B -1.45B -18.5B -1.4B -1.37B -59.01B
Projected Income Statement - Annual - Sunflower Pharmaceutical Group Co., Ltd.
Logo Sunflower Pharmaceutical Group Co., Ltd.
Sunflower Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company operates its businesses through three segments. The Headquarters Segment is responsible for investment management. The Pharmaceutical segment is mainly responsible for pharmaceutical production and sales. Other segment is mainly responsible for the production of packaging materials and the cultivation and research of Chinese herbal medicines. The Company’s main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in the domestic market.
Employees
5,025
Date Price Change Volume
26-10-20 CN¥11.25 -0.53% 2,984,009
26-10-19 CN¥11.31 +1.25% 3,734,153
26-10-16 CN¥11.17 +0.09% 4,937,269
26-10-15 CN¥11.16 -2.11% 3,942,800
26-10-14 CN¥11.40 +0.62% 2,915,458

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Sunflower Pharmaceutical Group Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 002737 Stock